Ticagrelor with or without Aspirin in High-Risk Patients after PCI

Mehran, Roxana; Baber, Usman; K. Sharma, Samin; J. Cohen, David; J. Angiolillo, Dominick; Briguori, Carlo; Y. Cha, Jin; Collier, Timothy; Dangas, George; Dudek, Dariusz; Džavík, Vladimír; Escaned, Javier; Gil, Robert; A. Gurbel, Paul; W. Hamm, Christian; D. Henry, Timothy; Huber, Kurt; Kastrati, Adnan; Kaul, Upendra; Kornowski, Ran; W. Krucoff, Mitchell; Kunadian, Vijay; O. Marx, Steven; R. Mehta, Shamir; J. Moliterno, David; Magnus Ohman, E.; G. Oldroyd, Keith; Sardella, Gennaro; Sartori, Samantha; Shlofmitz, Richard; Gabríel Steg, Philippe; Weisz, Giora; Witzenbichler, Bernhard; Han, Yaling; Pocock, Stuart; Michael Gibson, C.

doi:10.1056/nejmoa1908419

Public

Ticagrelor with or without Aspirin in High-Risk Patients after PCI

Published in New England Journal of Medicine • Sep 26, 2019

Authors:

Roxana Mehran

Usman Baber

Samin K. Sharma

Abstract

BACKGROUND: inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI). METHODS: In a double-blind trial, we examined the effect of ticagrelor alone as compared with ticagrelor plus aspirin with ...

Subject

Ticagrelor

Conventional PCI

Percutaneous coronary intervention

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!